323 related articles for article (PubMed ID: 33926423)
1. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.
Chen KY; Wu SM; Tseng CH; Lee KY; Lin YH; Liu HY; Chien LN
BMC Pulm Med; 2021 Apr; 21(1):141. PubMed ID: 33926423
[TBL] [Abstract][Full Text] [Related]
2. Use of antidiabetic medications and risk of chronic obstructive pulmonary disease exacerbation requiring hospitalization: a disease risk score-matched nested case-control study.
Wang MT; Lai JH; Huang YL; Kuo FC; Wang YH; Tsai CL; Tu MY
Respir Res; 2020 Dec; 21(1):319. PubMed ID: 33267895
[TBL] [Abstract][Full Text] [Related]
3. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
4. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
5. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones are associated with a reduced risk of COPD exacerbations.
Rinne ST; Liu CF; Feemster LC; Collins BF; Bryson CL; O'Riordan TG; Au DH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1591-7. PubMed ID: 26300638
[TBL] [Abstract][Full Text] [Related]
7. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
8. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
[TBL] [Abstract][Full Text] [Related]
10. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
12. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
Hsu CY; Su YW; Chen YT; Tsai SH; Chang CC; Li SY; Huang PH; Chen JW; Lin SJ
Cardiovasc Diabetol; 2016 Sep; 15(1):125. PubMed ID: 27585542
[TBL] [Abstract][Full Text] [Related]
13. Analysis of prevalence and prognosis of type 2 diabetes mellitus in patients with acute exacerbation of COPD.
Lin L; Shi J; Kang J; Wang Q
BMC Pulm Med; 2021 Jan; 21(1):7. PubMed ID: 33407328
[TBL] [Abstract][Full Text] [Related]
14. Does chronic obstructive pulmonary disease with or without type 2 diabetes mellitus influence the risk of lung cancer? Result from a population-based cohort study.
Shen TC; Chung WS; Lin CL; Wei CC; Chen CH; Chen HJ; Tu CY; Hsia TC; Shih CM; Hsu WH; Chung CJ
PLoS One; 2014; 9(5):e98290. PubMed ID: 24854189
[TBL] [Abstract][Full Text] [Related]
15. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.
Francis NA; Gillespie D; White P; Bates J; Lowe R; Sewell B; Phillips R; Stanton H; Kirby N; Wootton M; Thomas-Jones E; Hood K; Llor C; Cals J; Melbye H; Naik G; Gal M; Fitzsimmons D; Alam MF; Riga E; Cochrane A; Butler CC
Health Technol Assess; 2020 Mar; 24(15):1-108. PubMed ID: 32202490
[TBL] [Abstract][Full Text] [Related]
18. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
[TBL] [Abstract][Full Text] [Related]
19. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
